Loading...

Emerging Markets And Chronic Therapies Will Expand Global Horizons

Published
18 Nov 24
Updated
27 Aug 25
AnalystConsensusTarget's Fair Value
₹2,224.81
14.9% undervalued intrinsic discount
27 Aug
₹1,893.10
Loading
1Y
-15.5%
7D
-4.2%

Author's Valuation

₹2.2k

14.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 5.04%

Shared on23 Apr 25
Fair value Decreased 0.89%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.27%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.13%

AnalystConsensusTarget has decreased revenue growth from 9.7% to 6.1%, decreased profit margin from 16.0% to 14.2% and increased future PE multiple from 32.2x to 40.2x.

Shared on02 Apr 25
Fair value Increased 3.16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 0.20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.099%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 3.23%

AnalystConsensusTarget has decreased future PE multiple from 36.7x to 32.3x.